Published in Breast Cancer Res on January 01, 2013
Mitochondrial calcium uniporter activity is dispensable for MDA-MB-231 breast carcinoma cell survival. PLoS One (2014) 0.95
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res (2014) 0.94
The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma. Cancer Genomics Proteomics (2014) 0.86
A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Med (2015) 0.85
Downregulation of EphA5 by promoter methylation in human prostate cancer. BMC Cancer (2015) 0.85
Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech (2015) 0.83
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer (2014) 0.81
LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression. Oncogene (2014) 0.80
Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth. Mol Cancer Ther (2017) 0.78
WDR5 Expression Is Prognostic of Breast Cancer Outcome. PLoS One (2015) 0.78
Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer. PLoS One (2016) 0.78
ADAM10: a new player in breast cancer progression? Br J Cancer (2015) 0.78
Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies. BMJ Open (2015) 0.77
NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget (2016) 0.77
GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate. Biochim Biophys Acta (2016) 0.77
Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget (2016) 0.77
The C/EBPδ protein is stabilized by estrogen receptor α activity, inhibits SNAI2 expression and associates with good prognosis in breast cancer. Oncogene (2016) 0.76
Insights into Orphan Nuclear Receptors as Prognostic Markers and Novel Therapeutic Targets for Breast Cancer. Front Endocrinol (Lausanne) (2015) 0.75
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. Oncotarget (2017) 0.75
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. Br J Cancer (2016) 0.75
Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Res (2015) 0.75
MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol (2017) 0.75
Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis. PLoS One (2015) 0.75
LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget (2016) 0.75
Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells. Exp Cell Res (2016) 0.75
Automated Ki-67 Quantification of Immunohistochemical Staining Image of Human Nasopharyngeal Carcinoma Xenografts. Sci Rep (2016) 0.75
Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy. Clin Cancer Res (2015) 0.75
Prognostic factor analysis for breast cancer using gene expression profiles. BMC Med Inform Decis Mak (2016) 0.75
The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells. Sci Rep (2017) 0.75
Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: Association with clinical disease recurrence or metastasis. PLoS One (2017) 0.75
ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. FEBS Open Bio (2017) 0.75
Complex regulation of LCoR signaling in breast cancer cells. Oncogene (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res (2002) 40.03
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res (2005) 22.62
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol (2004) 15.15
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA (2005) 14.14
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Characterization of microRNA expression profiles in normal human tissues. BMC Genomics (2007) 8.01
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Targeted cancer therapy. Nature (2004) 7.81
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer (2002) 4.57
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
The protein tyrosine kinase family of the human genome. Oncogene (2000) 3.48
microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res (2011) 3.25
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics (2008) 3.24
BioMart Central Portal: an open database network for the biological community. Database (Oxford) (2011) 3.03
A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat (2010) 2.03
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer (2011) 2.01
Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer (2001) 1.72
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat (2008) 1.68
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res (2008) 1.66
Genome profiling of ERBB2-amplified breast cancers. BMC Cancer (2010) 1.53
Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat (2011) 1.47
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat (2008) 1.42
MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer (2008) 1.42
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis (2013) 1.32
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Is gene array testing to be considered routine now? Breast (2011) 1.25
Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia (2009) 1.24
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat (2011) 1.22
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics (2009) 1.19
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat (2008) 1.12
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer (2011) 1.02
Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res (2011) 1.00
Receptor tyrosine kinases: from biology to pathology. J Recept Signal Transduct Res (2011) 0.86
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. BMC Cancer (2011) 0.83
Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg (2011) 0.81
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (2008) 4.84
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 2.78
Fibulins: physiological and disease perspectives. EMBO Rep (2003) 2.56
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
Survivin: a new target for anti-cancer therapy. Cancer Treat Rev (2009) 2.37
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst (2004) 2.06
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res (2008) 2.01
Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol (2009) 1.99
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
In vitro demonstration of the heavy-atom effect for photodynamic therapy. J Am Chem Soc (2004) 1.74
Bioluminescent imaging: a critical tool in pre-clinical oncology research. J Pathol (2010) 1.64
Proliferation control strategies to improve productivity and survival during CHO based production culture : A summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines. Cytotechnology (2007) 1.63
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
The role of recombinant proteins in the development of serum-free media. Cytotechnology (2006) 1.57
A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2011) 1.55
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics (2011) 1.54
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer (2010) 1.54
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics (2011) 1.50
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One (2012) 1.50
Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Rev Mol Diagn (2008) 1.48
Intracellular and extracellular microRNAs in breast cancer. Clin Chem (2010) 1.44
Survivin: a promising tumor biomarker. Cancer Lett (2007) 1.41
MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma (2006) 1.38
p53 as a target for the treatment of cancer. Cancer Treat Rev (2014) 1.38
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest (2010) 1.38
Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Pathol (2008) 1.35
miRNA dysregulation in breast cancer. Cancer Res (2013) 1.35
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res (2006) 1.35
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res (2008) 1.34
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis (2013) 1.32
Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res (2007) 1.30
Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer (2009) 1.30
Role of ADAMs in cancer formation and progression. Clin Cancer Res (2009) 1.29
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
A personalized approach to cancer treatment: how biomarkers can help. Clin Chem (2008) 1.25
The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur J Cancer (2009) 1.24
Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat (2007) 1.22
An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol (2010) 1.20
The role of S100 genes in breast cancer progression. Tumour Biol (2010) 1.19
CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer (2007) 1.17
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther (2004) 1.17
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer (2010) 1.17
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer (2013) 1.16
Pre-exposure to yeast protects larvae of Galleria mellonella from a subsequent lethal infection by Candida albicans and is mediated by the increased expression of antimicrobial peptides. Microbes Infect (2006) 1.16
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol (2005) 1.15
Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. Methods Mol Biol (2011) 1.14
Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics (2011) 1.14
Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res (2012) 1.14
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med (2008) 1.13
JAM-A expression positively correlates with poor prognosis in breast cancer patients. Int J Cancer (2009) 1.13
RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Lett (2011) 1.13
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol (2009) 1.12
Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. Expert Opin Drug Metab Toxicol (2007) 1.11
Does a standardised scoring system of clinical signs reduce variability between doctors' assessments of the potentially dehydrated child? J Paediatr Child Health (2010) 1.11
Integrating transcription factor binding site information with gene expression datasets. Bioinformatics (2006) 1.10
Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. Biomaterials (2006) 1.10
Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther (2005) 1.10
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer (2008) 1.09
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res (2009) 1.09
Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol (2008) 1.08
Supramolecular photonic therapeutic agents. J Am Chem Soc (2005) 1.08
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One (2012) 1.08
Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer (2011) 1.07
Caspase 3 in breast cancer. Clin Cancer Res (2003) 1.06
A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Mod Pathol (2007) 1.05
miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin Cancer Res (2012) 1.04
Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta (2006) 1.03